Prostanoidien

Prostanoidien, often referred to as prostanoids, are a subclass of lipid compounds derived from arachidonic acid through the enzymatic action of cyclooxygenases (COX-1 and COX-2). These biologically active molecules play pivotal roles in various physiological and pathological processes, including inflammation, vascular function, and reproductive biology.

Prostanoids encompass several types, including prostaglandins, prostacyclins, and thromboxanes. Prostaglandins, such as PGE2, PGF2α, and PGI2 (prostacyclin), are involved in mediating inflammation, pain, vasodilation, and bronchoconstriction. Thromboxanes, primarily thromboxane A2, promote platelet aggregation and vasoconstriction, contributing to blood clot formation.

The biosynthesis of prostanoids begins with the release of arachidonic acid from membrane phospholipids, followed by its conversion to the unstable intermediate prostaglandin H2 (PGH2) via COX enzymes. PGH2 then serves as a substrate for specific synthases, producing the various prostanoids.

Prostanoids exert their effects by binding to specific G protein-coupled receptors (GPCRs), triggering diverse cellular responses. For example, PGE2 interacts with four receptor subtypes (EP1-EP4), mediating processes like fever, inflammation, and gastric mucosal protection.

Clinically, prostanoids are targeted by nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit COX enzymes to reduce prostanoid production, thereby alleviating inflammation and pain. Synthetic prostanoids are also used therapeutically for conditions such as pulmonary hypertension, glaucoma, and to prevent blood clotting.

Overall, prostanoidien are vital signaling molecules with broad influence on human health and disease, making them significant targets in pharmacology and medicine.